Pierre‐Yves Dumas

2.6k citations
45 papers · 1.2k indexed · 1 hit paper · h-index 13

Pierre‐Yves Dumas

41 papers receiving 1.2k citations

Hit Papers

Natural killer cells and other innate lymphoid cells in c...7542018202620202023250500750

Peers

Pierre‐Yves Dumas
Comparison fields: 5 of 85
  • Immunology 705
  • Hematology 309
  • Oncology 435
  • Genetics 91
  • Cancer Research 106
Replace Miwako Narita with:
Miwako Narita Japan
David G. Coffey United States
Amy E. Lin United States
Yuki Kagoya Japan
Wanhong Zhao China
Maya C. André Germany
Lino L. Teichmann Germany
Ingela B. Vikstrom Australia
Leonardo Mirandola United States
Fabrizio Carnevale‐Schianca Italy
Pierre‐Yves Dumas relative to Miwako Narita Japan Miwako Narita's profile →
Citations per field
00.5×4.0×
Miwako Narita · 1×
Citations per year

Countries citing papers authored by Pierre‐Yves Dumas

Since Specialization
Citations

This map shows the geographic impact of Pierre‐Yves Dumas's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Pierre‐Yves Dumas with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Pierre‐Yves Dumas more than expected).

Fields of papers citing papers by Pierre‐Yves Dumas

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Pierre‐Yves Dumas. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Pierre‐Yves Dumas. The network helps show where Pierre‐Yves Dumas may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Pierre‐Yves Dumas, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Pierre‐Yves Dumas Line = papers co-authored together Pierre‐Yves Dumas links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown
#Work
1 20250
2 20250
3 20251
4 20242
5 20241
6 20248
7 20237
8 20234
9 20230
10 20230
11 20222
12 20221
13 202124
14 202117
15 20212
16 20205
17 20207
18 201810
19 20189
20 201111

About Pierre‐Yves Dumas

Pierre‐Yves Dumas is a scholar working on Hematology, Genetics and Immunology, having authored 45 papers that have together received 1.2k indexed citations. Recurring topics across this work include Acute Myeloid Leukemia Research (29 papers), Chronic Myeloid Leukemia Treatments (9 papers), Acute Lymphoblastic Leukemia research (9 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (8 papers), Hematopoietic Stem Cell Transplantation (8 papers), Immune Cell Function and Interaction (6 papers), Chronic Lymphocytic Leukemia Research (5 papers) and Antifungal resistance and susceptibility (4 papers). The work is most often cited by research in Immunology (705 citations), Hematology (309 citations) and Oncology (435 citations). Pierre‐Yves Dumas has collaborated with scholars based in France, Italy and United States. Frequent co-authors include Éric Vivier, Margaux Vienne, Laura Chiossone, Arnaud Pigneux, Arnaud Villacreces, Jean‐Max Pasquet, Thibaut Leguay, Zoran Ivanović, Audrey Bidet and Vanessa Desplat. Their work appears in journals such as Journal of Clinical Oncology, Blood and Nature reviews. Immunology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026